Renaissance Technologies LLC Has $9.13 Million Position in AngioDynamics, Inc. $ANGO

Renaissance Technologies LLC lessened its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 4.7% in the 1st quarter, Holdings Channel reports. The firm owned 803,283 shares of the medical instruments supplier’s stock after selling 39,800 shares during the period. Renaissance Technologies LLC’s holdings in AngioDynamics were worth $9,133,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Millennium Management LLC grew its holdings in shares of AngioDynamics by 28.1% in the 3rd quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after buying an additional 393,682 shares during the period. Kotler Kevin acquired a new stake in AngioDynamics during the 4th quarter worth $21,997,000. Armistice Capital LLC lifted its holdings in AngioDynamics by 3.9% during the fourth quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock worth $21,828,000 after acquiring an additional 64,000 shares in the last quarter. Weber Capital Management LLC ADV bought a new position in AngioDynamics during the fourth quarter worth about $17,978,000. Finally, Bastion Asset Management Inc. grew its stake in AngioDynamics by 17.4% in the first quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock valued at $14,107,000 after acquiring an additional 194,822 shares during the period. 89.43% of the stock is currently owned by institutional investors and hedge funds.

AngioDynamics Price Performance

NASDAQ ANGO opened at $14.79 on Monday. The firm’s 50 day moving average is $12.81 and its 200-day moving average is $11.51. The company has a market capitalization of $611.27 million, a PE ratio of -17.00 and a beta of 0.33. AngioDynamics, Inc. has a 12-month low of $8.36 and a 12-month high of $15.19.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The business had revenue of $86.61 million during the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, sell-side analysts expect that AngioDynamics, Inc. will post -0.27 EPS for the current year.

Analyst Upgrades and Downgrades

ANGO has been the subject of several recent analyst reports. Freedom Capital upgraded AngioDynamics to a “strong-buy” rating in a report on Monday, April 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Zacks Research downgraded shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a report on Thursday, July 16th. Canaccord Genuity Group lifted their price target on shares of AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Finally, HC Wainwright upped their price target on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, AngioDynamics has a consensus rating of “Hold” and a consensus price target of $19.50.

Insider Buying and Selling at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the firm’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the transaction, the senior vice president owned 64,745 shares in the company, valued at $953,046.40. This trade represents a 26.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.00% of the stock is owned by insiders.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.